TABLE 3.

Laboratory Adverse Events According to CTCAE, Version 4.03

Adverse event	Grade 1	Grade 2	Grade 3
AST increased	22/31 (71%)	2/31 (6%)	5/31 (16%)
Platelet count decreased	22/31 (71%)	1/31 (3%)
INR increased	22/31 (71%)	2/31 (6%)
AP increased	19/31 (61%)	5/31 (16%)
Anemia	16/31 (52%)	5/31 (16%)	2/31 (6%)
ALT increased	15/31 (48%)	2/31 (6%)
Hypoalbuminemia	14/31 (45%)	5/31 (16%)	1/31 (3%)
Prolonged APTT	13/31 (42%)	2/31 (6%)
Hyponatremia	12/31 (39%)		3/31 (10%)
Hypokalemia	9/31 (29%)
Hyperglycemia	9/31 (29%)	13/31 (42%)	6/31 (19%)
Creatinine increased	7/31 (23%)	1/31 (3%)
Bilirubin increased	6/31 (19%)	4/31 (13%)	1/31 (3%)
GGT increased	5/31 (16%)	9/31 (29%)	14/31 (45%)
Hypoglycemia	3/31 (10%)
Lymphopenia	1/31 (3%)	13/31 (42%)	9/31 (29%)

AST = aspartate transaminase; INR = international normalized ratio; AP = alkaline phosphatase; ALT = alanine transaminase; APTT = activated prothrombin time; GGT = γ-glutamyltransferase.

This table represents new and highest toxicity during 6-mo follow-up. No laboratory adverse events grade 4 or 5 were observed.